1H-3-BENZAZEPIN-7-OL, 5-(7-BENZOFURANYL)-8-CHLORO-2,3,4,5-TETRAHYDRO-3-METHYL-, (5S)-
Aggressive B-cell Lymphoma With Secondary Involvement of the CNS
National Cancer Institute (NCI)Small moleculePhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 28/ 100
- Competitive Position
- 95/ 100
Competitive context
12 Active assets in the Aggressive B-cell Lymphoma With Secondary Involvement of the CNS cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Benadryl National Cancer Institute (NCI) | Phase 1 | CC |
Ketorolac Tromethamine National Cancer Institute (NCI) | Phase 1 | CC |
FENTANYL National Cancer Institute (NCI) | Phase 1 | CC |
Venetoclax National Cancer Institute (NCI) | Phase 1 | CC |
(±)-1-BUTYL-2',6'-PIPECOLOXYLIDIDE MONOHYDROCHLORIDE National Cancer Institute (NCI) | Phase 1 | CC |
View all 12 →
Same molecule, other indications
1H-3-BENZAZEPIN-7-OL, 5-(7-BENZOFURANYL)-8-CHLORO-2,3,4,5-TETRAHYDRO-3-METHYL-, (5S)- is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →